These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 29354118)
1. Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference. Chartrand K; Lebel MÈ; Tarrab E; Savard P; Leclerc D; Lamarre A Front Immunol; 2017; 8():1885. PubMed ID: 29354118 [TBL] [Abstract][Full Text] [Related]
3. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling. Thérien A; Bédard M; Carignan D; Rioux G; Gauthier-Landry L; Laliberté-Gagné MÈ; Bolduc M; Savard P; Leclerc D J Nanobiotechnology; 2017 Jul; 15(1):54. PubMed ID: 28720097 [TBL] [Abstract][Full Text] [Related]
4. Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine. Rioux G; Carignan D; Russell A; Bolduc M; Gagné MÈ; Savard P; Leclerc D J Nanobiotechnology; 2016 Jun; 14(1):43. PubMed ID: 27282291 [TBL] [Abstract][Full Text] [Related]
5. Complement Component 3 Regulates IFN-α Production by Plasmacytoid Dendritic Cells following TLR7 Activation by a Plant Virus-like Nanoparticle. Lebel MÈ; Langlois MP; Daudelin JF; Tarrab E; Savard P; Leclerc D; Lamarre A J Immunol; 2017 Jan; 198(1):292-299. PubMed ID: 27864474 [TBL] [Abstract][Full Text] [Related]
6. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine. Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362 [TBL] [Abstract][Full Text] [Related]
9. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159 [TBL] [Abstract][Full Text] [Related]
10. Multiple mechanisms contribute to impairment of type 1 interferon production during chronic lymphocytic choriomeningitis virus infection of mice. Lee LN; Burke S; Montoya M; Borrow P J Immunol; 2009 Jun; 182(11):7178-89. PubMed ID: 19454715 [TBL] [Abstract][Full Text] [Related]
11. Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus. Acosta-Ramírez E; Pérez-Flores R; Majeau N; Pastelin-Palacios R; Gil-Cruz C; Ramírez-Saldaña M; Manjarrez-Orduño N; Cervantes-Barragán L; Santos-Argumedo L; Flores-Romo L; Becker I; Isibasi A; Leclerc D; López-Macías C Immunology; 2008 Jun; 124(2):186-97. PubMed ID: 18070030 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the immunomodulatory and antiviral effects of the cytokine combination IFN-α and IL-7 in the lymphocytic choriomeningitis virus and Friend retrovirus mouse infection models. Audigé A; Hofer U; Dittmer U; van den Broek M; Speck RF Viral Immunol; 2011 Oct; 24(5):375-85. PubMed ID: 21929334 [TBL] [Abstract][Full Text] [Related]
14. Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity. Laliberté-Gagné ME; Bolduc M; Garneau C; Olivera-Ugarte SM; Savard P; Leclerc D Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33435570 [TBL] [Abstract][Full Text] [Related]
15. Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform. Laliberté-Gagné MÈ; Bolduc M; Thérien A; Garneau C; Casault P; Savard P; Estaquier J; Leclerc D Vaccines (Basel); 2019 Jun; 7(2):. PubMed ID: 31212772 [No Abstract] [Full Text] [Related]
16. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774 [TBL] [Abstract][Full Text] [Related]
17. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. Leclerc D; Beauseigle D; Denis J; Morin H; Paré C; Lamarre A; Lapointe R J Virol; 2007 Feb; 81(3):1319-26. PubMed ID: 17121795 [TBL] [Abstract][Full Text] [Related]
18. IL-12 is not required for induction of type 1 cytokine responses in viral infections. Oxenius A; Karrer U; Zinkernagel RM; Hengartner H J Immunol; 1999 Jan; 162(2):965-73. PubMed ID: 9916721 [TBL] [Abstract][Full Text] [Related]
19. Antagonism or synergism between papaya ringspot virus and papaya mosaic virus in Carica papaya is determined by their order of infection. Chávez-Calvillo G; Contreras-Paredes CA; Mora-Macias J; Noa-Carrazana JC; Serrano-Rubio AA; Dinkova TD; Carrillo-Tripp M; Silva-Rosales L Virology; 2016 Feb; 489():179-91. PubMed ID: 26765969 [TBL] [Abstract][Full Text] [Related]
20. A role for the transcription factor RelB in IFN-alpha production and in IFN-alpha-stimulated cross-priming. Le Bon A; Montoya M; Edwards MJ; Thompson C; Burke SA; Ashton M; Lo D; Tough DF; Borrow P Eur J Immunol; 2006 Aug; 36(8):2085-93. PubMed ID: 16810633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]